SCYNEXIS, Inc. (SCYX) Financial Statements (2024 and earlier)

Company Profile

Business Address 1 EVERTRUST PLAZA
JERSEY CITY, NJ 07302-6548
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:91,90054,80073,50096,100118,69195,210
Cash and cash equivalents57,90526,91345,81468,620118,69195,210
Short-term investments27,63727,90827,68927,470  
Other undisclosed cash, cash equivalents, and short-term investments6,358(21)(3)10  
Restricted cash and investments435555555  
Receivables2,3452,0602,1012,4932,2111,628
Inventory, net of allowances, customer advances and progress billings10,2901,1058997866291,149
Inventory10,2901,1058997866291,149
Prepaid expense1,1668661,8063,2803,6433,162
Contract with customer, asset, after allowance for credit loss19,249     
Other current assets1,11029162444
Other undisclosed current assets19,035590638847498753
Total current assets:145,53059,76779,061103,565125,676101,906
Noncurrent Assets
Operating lease, right-of-use asset2,4842,5402,5942,6462,6972,749
Property, plant and equipment      61
Intangible assets, net (including goodwill)206309408770866961
Intangible assets, net (excluding goodwill)206309408770866961
Restricted cash and investments163163163163218218
Deferred costs7373737373124
Other noncurrent assets647,4445,5115,0766,0825,543
Other undisclosed noncurrent assets6,336     
Total noncurrent assets:9,32610,5298,7498,7289,9369,656
TOTAL ASSETS:154,85670,29687,810112,293135,612111,562
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,60610,70011,56515,09615,35612,653
Employee-related liabilities1,821
Accounts payable3,4165,9255,9377,4199,9608,130
Accrued liabilities7,1904,7755,6285,8565,3964,523
Deferred revenue3,229     
Debt  34,648    
Other liabilities   5,771720457174
Other undisclosed current liabilities2,323296282(1,552)199117
Total current liabilities:16,15845,64417,61814,26416,01212,944
Noncurrent Liabilities
Long-term debt and lease obligation   34,39337,16037,01036,851
Long-term debt, excluding current maturities   34,39334,16233,93933,713
Liabilities, other than long-term debt3,9002,8422,9214,8985,0614,102
Deferred revenue1,140     
Other liabilities    4,8985,0614,102
Operating lease, liability2,7602,8422,9212,9983,0713,138
Other undisclosed noncurrent liabilities41,72051,72429,64538,76232,04918,738
Total noncurrent liabilities:45,62054,56666,95980,82074,12059,691
Total liabilities:61,778100,21084,57795,08490,13272,635
Equity
Equity, attributable to parent, including:93,078(29,914)3,23317,20945,48038,927
Additional paid in capital426,942426,214425,485425,032423,719403,825
Accumulated deficit(333,904)(456,164)(422,288)(407,859)(378,275)(364,930)
Other undisclosed equity, attributable to parent403636363632
Total equity:93,078(29,914)3,23317,20945,48038,927
TOTAL LIABILITIES AND EQUITY:154,85670,29687,810112,293135,612111,562

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues131,4541,1301,5241,5571,323687
Gross profit:131,4541,1301,5241,5571,323687
Operating expenses(14,940)(11,812)(24,005)(23,358)(23,061)(20,425)
Operating income (loss):116,514(10,682)(22,481)(21,801)(21,738)(19,738)
Nonoperating income (expense)5,746(23,194)8,052(7,783)8,3939,587
Interest and debt expense(1,249)(1,447)(1,529)(1,379)(1,231)(1,059)
Income (loss) from continuing operations before equity method investments, income taxes:121,011(35,323)(15,958)(30,963)(14,576)(11,210)
Other undisclosed income from continuing operations before income taxes1,2491,4471,5291,3791,2311,059
Income (loss) from continuing operations before income taxes:122,260(33,876)(14,429)(29,584)(13,345)(10,151)
Income tax benefit      4,700
Income (loss) from continuing operations:122,260(33,876)(14,429)(29,584)(13,345)(5,451)
Loss before gain (loss) on sale of properties:(29,584)(13,345)(5,451)
Net income (loss) available to common stockholders, basic:122,260(33,876)(14,429)(29,584)(13,345)(5,451)
Dilutive securities, effect on basic earnings per share 433    (584)
Net income (loss) available to common stockholders, diluted:122,693(33,876)(14,429)(29,584)(13,345)(6,035)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):122,260(33,876)(14,429)(29,584)(13,345)(5,451)
Comprehensive income (loss), net of tax, attributable to parent:122,260(33,876)(14,429)(29,584)(13,345)(5,451)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: